From bespoke to scalable: closing the manufacturing gap in advanced therapeutics

Published: 20-May-2026
Manufacturing Cell & Gene Therapy

Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics

You need to be a subscriber to read this article.
Click here to find out more.

Cytiva’s 2025 Global Biopharma Index reveals that manufacturing agility and digital maturity are now key differentiators throughout the industry.

Yet many companies are still working to move from bespoke, manual processes to systems that can scale reliably and consistently.

The organisations making progress share a common approach: investing in real-time analytics, automation and digitally integrated manufacturing.

These capabilities are helping improve batch consistency, accelerate release timelines and reduce waste — ultimately making it possible to bring advanced therapeutics to more patients, faster. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Cytiva
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Cytiva enters research partnership with SRTIGET for next-gen genomic medicine

Read more
The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
  3. Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
  4. Lonza delivers strong performance in Q1 2026 in line with expectations and confirms full-year Outlook 2026 Basel, Switzerland, 8 May 2026 – In its qualitative Q1 2026 business update, Lonza1 reported a strong performance across its CDMO business in line with the expected trajectory for Full-Year 2026. As expected, due to a lower prior year base, campaign timing and product releases, and planned site shutdowns, CER sales growth and CORE EBITDA margin will be notably stronger in the first half of 2026 than in the second half
  5. Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Cytiva enters research partnership with SRTIGET for next-gen genomic medicine

The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
Cell & Gene Therapy

Cytiva and WhiteLab Genomics team up to use AI to accelerate cell line development

Collaboration will accelerate stable cell line development in AAV genomic medicine development and ultimately also shorten the development timeline to clinic
Manufacturing

Cytiva and Culture Biosciences expand strategic collaboration

Strengthened collaboration to accelerate bioprocessing innovation and global distribution
Manufacturing

Cytiva unveils new ÄKTA readyflux system for low-volume drug manufacturing

Single-use platform designed to streamline technology transfers, improve consistency and reduce downtime
Manufacturing

Cytiva broadens Xcellerex X-platform to include 500L and 2 000L bioreactors

New single-use bioreactors improve scalability and efficiency for advanced therapeutics
Manufacturing

Cytiva and Cellular Origins team up to advance the cell and gene therapy manufacturing process

By combining Cytiva's Sefia platform with Cellular Origins' automated Constellation platform, the two will help its customers to efficiently scale up CGT production to industrial levels
Manufacturing

Multiply Labs' robotic pharmaceutical manufacturing project reaches proof-of-concept

The consortium which contains Multiply Labs, Thermo Fisher, Cytiva, UCSF and Charles River has reached proof-of-concept on a robotic and automated cell manufacturing system
Subscribe now